News & Events
An experiment in end-of-life care: Tapping AI’s cold calculus to nudge the most human of conversations
https://www.statnews.com/2020/07/01/end-of-life-artificial-intelligence/
Cancer Care Associates of York Joins the Quality Cancer Care Alliance’s National Network
https://www.newswire.com/news/cancer-care-associates-of-york-joins-the-quality-cancer-care-alliances-21160679
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
https://www.ncbi.nlm.nih.gov/pubmed/30487236 Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC,… A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
Aligning With Cancer Centers To Spur Biosimilar Uptake
https://www.biosimilardevelopment.com/doc/aligning-with-cancer-centers-to-spur-biosimilar-uptake-0001
Reducing Cancer Costs Through Symptom Management and Triage Pathways.
Barkley R1, Soobader MJ2, Wang J2, Blau S3, Page RD4.https://www.ncbi.nlm.nih.gov/pubmed/30576262
What Is Data Science: Addressing the Uncertainty Behind Addressing Uncertainty
https://www.journalofclinicalpathways.com/commentary/what-data-science-addressing-uncertainty-behind-addressing-uncertainty
Artificial intelligence (AI) to improve patient outcomes in community oncology practices.
https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e18098
Empower Physicians to Fight Financial Toxicity With Biosimilars
Author: Kathy Oubre, MS https://www.ajmc.com/journals/evidence-based-oncology/2019/december-2019/empower-physicians-to-fight-financial-toxicity-with-biosimilars
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Slamon DJ1, Neven P1, Chia S1, Fasching PA1, De Laurentiis M1, Im SA1, Petrakova K1, Val Bianchi G1, Esteva FJ1, Martín M1, Nusch A1, Sonke GS1, De la Cruz-Merino L1, Beck JT1, Pivot X1, Sondhi M1, Wang Y1, Chakravartty A1, Rodriguez-Lorenc K1, Taran T1, Jerusalem… Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.